Trevi Therapeutics, Inc. is a late stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch).

News
Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting of the American College of Clinical Pharmacology
9/9/2014
Title of Abstract: Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses
Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic Pruritus
7/14/2014
Study will enroll 360 patients in the United States and Europe